Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018. by Getachew Ossabo Babore (10788843)

During electrical stimulation the decrease in compound action potential (CAP), but not of ATP, is larger in <i>Plp</i>^null/y mice. by Andrea Trevisiol (9647910)

<i>T. cruzi</i> PCM abrogates MAP kinase activation and decreased MAP kinase signaling results in inhibition of ctgf/ccn2 expression. by G. Adam Mott (198973)

siRNAs against CCT-eta and CCT-beta decrease both basal and EGF- induced mRNA and protein levels of their targets in fibroblasts. by Latha Satish (365152)

“…Results are expressed as relative quotient (RQ) of measured CCT-eta or CCT-beta mRNA and were calculated as a percentage of baseline control levels (100%). …”

KYNA and zaprinast decrease the [Ca²⁺]i plateau phase following an IP3-mediated stimulus in mouse cortical astrocytes. by Rolando Berlinguer-Palmini (491113)

“…<b>E</b>) Time course of MRS-1845, D-APV (50 µM) and MLA (100 nM) effects on fluo-3 fluorescence in a single astrocyte in cultures. …”

Transient kinetic analysis of the S100A4-N-ERMAD interaction. by Beáta Biri-Kovács (4020650)

“…<p>(A, B) 2 μM N-ERMAD or F2 lobe (respectively) was mixed with an equal volume of S100A4 in different concentrations and a decrease in intrinsic Trp fluorescence was monitored over time (left panel). …”

<b>Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons</b> by Muhammad Saad Yousuf (20745168)

Expression of vTR harboring the mutant template (AU5) decreases cell proliferation of an avian cancer cell line. by Benedikt B. Kaufer (341018)

AKP-11 and FTY720 prevent the infiltration of mononuclear cells into the CNS of EAE animals and decrease the inflammatory cytokines and protect the MBP and NF-200. by Devadoss J. Samuvel (327215)